Blueprint Medicines (NASDAQ:BPMC) Downgraded by StockNews.com to Sell
Blueprint Medicines (NASDAQ:BPMC – Get Free Report) was downgraded by investment analysts at StockNews.com from a “hold” rating to a “sell” rating in a research note issued on Thursday. Other equities research analysts have also issued research reports about the stock. Guggenheim upped their price target on shares of Blueprint Medicines from $130.00 to $138.00 […]
More Stories
Judge Orders Month-Long Pause on Process for Alberta Separation Referendum Petition
By Olivia Gomm An Alberta judge has granted a one-month stay on the validation process of a petition to trigger...
US to Blockade Strait of Hormuz After US–Iran Talks End Without Deal, Trump Says
By Jacki Thrapp The U.S. Navy will begin blockading the Strait of Hormuz after peace talks with Iran ended without...
US Property Taxes Grow 3 Percent on Average in 2025, Outpacing Inflation
By Rob Sabo Property taxes are rising across the United States and, on average, have outpaced inflation. Homeowners in 2025...
Shane Lowry Makes Golf History With His 2nd Masters Hole-in-One
By Ross Kelly There are millions of casual golfers around the world who dream some day of recording an ace...
Treasury, IRS Propose Rules for 1 Percent Remittance Tax on Some Money Sent to Foreign Countries
By Naveen Athrappully The Internal Revenue Service and the Department of the Treasury proposed regulations on Friday regarding the new...
Hezbollah Leader Says Group Would Continue to Fight Israel After Strikes
By Jack Phillips The leader of Lebanese terrorist organization Hezbollah has said that his group would continue to fight Israel,...